Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Elite Pharma Inc
(OP:
ELTP
)
0.1325
+0.0030 (+2.32%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
290,097
Open
0.1290
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1295
Today's Range
0.1270 - 0.1328
52wk Range
0.0291 - 0.2100
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
February 14, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
February 08, 2024
Via
ACCESSWIRE
Performance
YTD
-4.88%
-4.88%
1 Month
-13.40%
-13.40%
3 Month
-30.26%
-30.26%
6 Month
+12.48%
+12.48%
1 Year
+301.52%
+301.52%
More News
Read More
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
December 26, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
December 12, 2023
Via
ACCESSWIRE
Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024
December 04, 2023
Via
InvestorPlace
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
November 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
August 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
August 09, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
November 10, 2023
Via
ACCESSWIRE
7 Penny Stocks With Promising Potential Catalysts in 2024
November 09, 2023
Via
InvestorPlace
Q4 Stock Predictions: 7 Penny Stocks Ready to Roar Into 2024
October 09, 2023
Via
InvestorPlace
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
September 25, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
September 07, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
June 29, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
June 22, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
February 14, 2023
Via
ACCESSWIRE
7 Up-and-Coming Penny Stocks to Put on Your Must-Buy List
September 04, 2023
Via
InvestorPlace
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
August 28, 2023
Via
ACCESSWIRE
7 OTC Stocks to Buy With Boatloads of Potential
June 07, 2023
Via
InvestorPlace
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
May 03, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
April 20, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
November 15, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
February 07, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
December 22, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
November 08, 2022
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.